Equities

Hims & Hers Health Inc

Hims & Hers Health Inc

Actions
Health CareHealth Care Providers
  • Price (USD)6.81
  • Today's Change0.095 / 1.42%
  • Shares traded141.39k
  • 1 Year change+13.04%
  • Beta--
Data delayed at least 15 minutes, as of Dec 06 2022 15:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Hims & Hers Health, Inc., formerly Oaktree Acquisition Corp., is a telehealth platform that connects consumers to licensed healthcare professionals. The Company has designed and build a cloud-based technology, through which it offers a range of health and wellness products and services. Its platform helps customers to access medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more. The Company has partnered with dermatology experts to offer access to formulated topical creams for customers experiencing acne and signs of premature aging, such as wrinkles. It offers telehealth solutions with combined access to a distributed provider network, digital prescriptions, cloud pharmacy, and consumer engagement strategies, all delivered through mobile and Web interfaces. The Company's Products include shampoo, conditioner, biotin gummies, anti-aging cream, vitamin c serum, acne cream and moisturizer.

  • Revenue in USD (TTM)373.75m
  • Net income in USD-83.03m
  • Incorporated2021
  • Employees398.00
  • Location
    Hims & Hers Health Inc2269 Chestnut St, #523SAN FRANCISCO 94123United StatesUSA
  • Phone+1 (415) 851-0195
  • Fax+1 (302) 655-5049
  • Websitehttps://www.forhims.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Travere Therapeutics Inc213.40m-264.23m1.28bn310.00--12.75--6.02-4.18-4.183.381.570.28431.1216.39688,383.90-35.20-21.88-42.04-25.9296.3697.04-123.82-73.534.03-24.570.7884--14.7111.234.61--15.16--
Verve Therapeutics Inc929.00k-147.64m1.32bn113.00--2.36--1,420.40-2.90-2.900.01839.070.0017----8,221.24-27.23---28.53-------15,892.25------0.00-------163.25------
Medifast Inc1.64bn151.07m1.33bn984.009.208.808.350.808313.1813.18143.0113.774.703.30--1,665,818.0043.3040.9978.9864.9172.3074.689.2210.780.5465324.700.0047.6163.2540.9359.4755.8664.0939.63
Allogene Therapeutics Inc247.00k-312.65m1.35bn356.00--1.83--5,476.48-2.20-2.200.00175.140.0003----796.77-31.79---33.54-------126,580.20------0.00-------2.71------
BridgeBio Pharma Inc88.66m-490.77m1.37bn576.00------15.46-3.35-3.350.6054-7.620.1174----153,930.60-65.73---77.58--95.11---559.83------2.99--745.14---25.36------
Keros Therapeutics Inc20.00m-81.90m1.38bn104.00--5.41--68.86-3.36-3.360.82459.240.0829--126.98333,333.30-33.95---35.61-------409.51-----43,848.000.00-------29.01------
Novavax Inc1.85bn-1.32bn1.38bn1.54k------0.7486-17.25-17.2523.84-7.210.7641--16.671,198,360.00-54.70-70.99-187.25-148.0948.93---71.59-156.111.01-60.34----141.02136.93-316.91--25.86--
Hims & Hers Health Inc373.75m-83.03m1.39bn398.00--4.35--3.73-0.411-0.4111.851.541.037.22120.92939,067.80-22.82---25.76--74.62---22.22--3.79-421.020.00-------3,430.95------
Cassava Sciences Inc0.00-71.28m1.41bn24.00--6.80-----1.78-1.780.004.960.00----0.00-29.61-21.19-30.53-22.05------------0.00-------411.29--212.11--
Amphastar Pharmaceuticals Inc484.85m77.23m1.42bn1.76k19.732.8313.772.931.491.499.3210.390.70352.476.25275,327.1011.403.9613.345.0348.2540.8916.206.572.75159.720.13030.0025.1311.404,327.3744.625.13--
Reata Pharmaceuticals Inc3.15m-311.78m1.45bn346.00--321.26--461.04-8.55-8.550.08640.12330.0048----9,101.16-47.40-40.52-54.53-50.27-----9,901.05-663.02----0.00--27.40-25.44-10.16--31.34--
Chinook Therapeutics Inc56.85m-117.77m1.46bn138.00--3.06--25.61-1.83-1.830.94827.440.1168--38.81411,971.00-24.19-22.27-26.02-24.07-----207.14-441.76---27.860.00--6,142.440.3698-26.11---39.87--
Rocket Pharmaceuticals Inc0.00-199.39m1.50bn151.00--3.51-----3.06-3.060.005.410.00----0.00-42.09-31.02-44.66-32.83------------0.054-------21.02--87.27--
SpringWorks Therapeutics Inc0.00-259.31m1.51bn222.00--2.47-----5.19-5.190.009.820.00----0.00-44.07---47.18-------------272.170.0093---100.00---281.60------
Data as of Dec 06 2022. Currency figures normalised to Hims & Hers Health Inc's reporting currency: US Dollar USD

Institutional shareholders

17.77%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 202210.83m5.45%
BlackRock Fund Advisorsas of 30 Sep 20227.44m3.75%
Oaktree Capital Management LPas of 30 Sep 20223.27m1.65%
SSgA Funds Management, Inc.as of 30 Sep 20223.02m1.52%
Marshall Wace LLPas of 30 Sep 20222.25m1.13%
Geode Capital Management LLCas of 30 Sep 20222.12m1.07%
Franklin Advisers, Inc.as of 30 Sep 20221.79m0.90%
Canada Pension Plan Investment Boardas of 30 Sep 20221.58m0.79%
Renaissance Technologies LLCas of 30 Sep 20221.51m0.76%
American Century Investment Management, Inc.as of 30 Sep 20221.49m0.75%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.